Italia markets open in 7 hours 1 minute

Codexis, Inc. (CDXS)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
3,5600-0,1300 (-3,52%)
Alla chiusura: 04:00PM EDT
3,5500 -0,01 (-0,28%)
Dopo ore: 06:04PM EDT

Codexis, Inc.

200 Penobscot Drive
Redwood City, CA 94063
United States
650 421 8100
https://www.codexis.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno174

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Stephen George Dilly MBBS, Ph.D.President, CEO & Director1,88MN/D1960
Mr. Sriram Ryali M.B.A.Chief Financial Officer770,45kN/D1981
Mr. Kevin Norrett M.B.A., M.S.Chief Operating Officer739,56kN/D1973
Carrie McKimDirector of Investor RelationsN/DN/DN/D
Ms. Margaret Nell Fitzgerald J.D.Chief Legal & Compliance Officer, General Counsel and Secretary300,03kN/D1971
Ms. Karen Frechou-ArmijoSenior VP & Head of Human ResourcesN/DN/DN/D
Dr. Stefan Lutz Ph.D.Senior Vice President of ResearchN/DN/DN/D
Mr. Robert Sato M.B.A., Ph.D.Senior Vice President of Pharmaceutical Development, Quality & RegulatoryN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Governance aziendale

L'ISS Governance QualityScore di Codexis, Inc. al 1 luglio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 3; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.